Abstract:<p>Pathological cardiac remodeling, characterized by excessive deposition of extracellular matrix proteins and cardiac hypertrophy, leads to the development of heart failure. Meprin α (Mep1a), a zinc metalloprotease, previously reported to participate in the regulation of inflammatory response and fibrosis, may also contribute to cardiac remodeling, although whether and how it participates in this process remains unknown. Here, in this work, we investigated the role of Mep1a in pathological cardiac remodeling, as well as the effects of the Mep1a inhibitor actinonin on cardiac remodeling-associated phenotypes. We found that Mep1a deficiency or chemical inhibition both significantly alleviated TAC- and Ang II-induced cardiac remodeling and dysfunction. Mep1a deletion and blocking both attenuated TAC- and Ang II-induced heart enlargement and increases in the thickness of the left ventricle anterior and posterior walls, and reduced expression of pro-hypertrophic markers, including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and myosin heavy chain beta (β-MHC). In addition, Mep1a deletion and blocking significantly inhibited TAC- and Ang II-induced cardiac fibroblast activation and production of extracellular matrix (ECM). Moreover, in Mep1a<sup>−/−</sup> mice and treatment with actinonin significantly reduced Ang II-induced infiltration of macrophages and proinflammatory cytokines. Notably, we found that in vitro, Mep1a is expressed in cardiac myocytes and fibroblasts and that Mep1a deletion or chemical inhibition both markedly suppressed Ang II-induced hypertrophy of rat or mouse cardiac myocytes and activation of rat or mouse cardiac fibroblasts. In addition, blocking Mep1a in macrophages reduced Ang II-induced expression of interleukin (IL)-6 and IL-1β, strongly suggesting that Mep1a participates in cardiac remodeling processes through regulation of inflammatory cytokine expression. Mechanism studies revealed that Mep1a mediated ERK1/2 activation in cardiac myocytes, fibroblasts and macrophages and contributed to cardiac remodeling. In light of our findings that blocking Mep1a can ameliorate cardiac remodeling via inhibition of cardiac hypertrophy, fibrosis, and inflammation, Mep1a may therefore serve as a strong potential candidate for therapeutic targeting to prevent cardiac remodeling.</p>

Imidaprilat Inhibits Matrix Metalloproteinase-2 Activity in Human Cardiac Fibroblasts Induced by Interleukin-1Β Via NO-dependent Pathway

Effects of Imidaprilat on Matrix Metalloproteinase - 2 and TIMP - 2 in Human Cardiac Fibroblasts

[Interleukin-1Beta Upregulates Matrix Metalloproteinase-2 Expression and Activity in Cardiac Fibroblasts Via Nitric Oxide Synthase Pathway].

Tissue Inhibitor of Matrix Metalloproteinase-1 in Norepinephrine-Induced Remodeling of the Mouse Heart

Inhibition of Histone Demethylase JMJD1C Attenuates Cardiac Hypertrophy and Fibrosis Induced by Angiotensin II

Intermedin 1-53 Inhibits Myocardial Fibrosis in Rats by Down-Regulating Transforming Growth Factor-β

[The Influence of Angiotensin II Receptor Blockade on the Expressions of Col I and TIMP-1 Mrna in Cardiac Fibroblast of Adult Rat].

Intermedin1–53 inhibits rat cardiac fibroblast activation induced by angiotensin II

ACE2 is a negative regulator of profilin-1 expression and collagen production in cultured adult murine cardiomyocytes

ANGIOTENSIN II-MEDIATED MYOCARDIAL EXPRESSION OF MMP2, MMP9 AND MT1-MMP WERE ENHANCED IN ACE2-NULL MICE

Matrix Metalloproteinase 3 Regulates Angiotensin II‑induced Myocardial Fibrosis Cell Viability, Migration and Apoptosis.

The Ace2-Ang (1-7)-mas Receptor Axis Attenuates Cardiac Remodeling and Fibrosis in Post-Myocardial Infarction

Mep1a contributes to Ang II-induced cardiac remodeling by promoting cardiac hypertrophy, fibrosis and inflammation

Angiotensin II-induced Matrix Metalloproteinase-8 is Regulated by Angiotensin-(1-7) in Vascular Smooth Muscle Cells

Angiotensin II Induced Differentially Expressed Micrornas in Adult Rat Cardiac Fibroblasts

Effects of Β-Adrenergic Eceptor Blockers on Cardiac Fibrosis During Heart Failure after Myocardial Infarction in Rats

Intermedin1-53 Inhibits NLRP3 Inflammasome Activation by Targeting IRE1α in Cardiac Fibrosis

Agonists at PPAR‐γ Suppress Angiotensin II‐induced Production of Plasminogen Activator Inhibitor‐1 and Extracellular Matrix in Rat Cardiac Fibroblasts

Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade

Levocarnitine regulates the growth of angiotensin II-induced myocardial fibrosis cells via TIMP-1

Angiotensin Converting Enzyme Inhibitors (ACEIs) Decrease the Progression of Cardiac Fibrosis in Rheumatic Heart Disease Through the Inhibition of IL-33/sST2